This label expansion in Japan is a positive catalyst for Arexvy's commercial trajectory, though the near-term revenue impact is likely modest given the at-risk subpopulation within 18-49. Monitor Japan's national immunization recommendations and uptake rates in the upcoming RSV season. The cross-filing with the 20-F annual report provides context on GSK's broader financial health but does not change the standalone read on this regulatory win.
Price Chart
Executive Summary
GSK announced that Japan's MHLW expanded approval of its RSV vaccine Arexvy to include adults aged 18-49 at increased risk, making it the first RSV vaccine approved for all at-risk adults in Japan. The label was also updated to explicitly include immunocompromised patients as an increased risk group. This expands the addressable population in Japan, where over 42 million adults are aged 18-49, though no specific revenue or market size figures were provided.
Key Facts
- Japan MHLW expanded Arexvy approval to adults aged 18-49 at increased risk for RSV disease
- First RSV vaccine approved for all at-risk adults in Japan (18-49 AIR, 50-59 AIR, and 60+)
- Prescribing information updated to explicitly include immunocompromised patients as an increased risk group
- Approval supported by Phase IIIb trial (NCT06389487) showing non-inferior immune response vs adults 60+
- Arexvy already approved in 70 countries for 60+, 60+ countries for 50-59 AIR, US for 18-49 AIR, and EEA for all adults 18+
- Over 42 million adults in Japan are aged 18-49, with many having underlying chronic conditions
Financial Impact
Expanded label in Japan adds a large addressable population (42M+ adults 18-49) but no specific revenue contribution or market size was disclosed. Arexvy is already approved in 70+ countries for older adults.
Risk Factors
- Competition from Pfizer's RSV vaccine Abrysvo and other entrants in Japan
- Uptake may be limited by lack of routine RSV testing and awareness among younger adults
- No specific revenue guidance or market size provided for the expanded indication
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-005024 |
| Document: 0001654954-26-005024-index-headers.html | 0001654954-26-005024 |
| Document: 0001654954-26-005024-index.html | 0001654954-26-005024 |
| Document: 0001654954-26-005024.txt | 0001654954-26-005024 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 19w ago | 6-K | $25.12 $25.25 | ▲ +0.52% | ▼ −1.62% | $26.12 (+3.98%) |
Jun 9, 2026 19w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 9, 2026 20w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
May 28, 2026 21w ago | 6-K | $24.58 $24.66 | ▲ +0.33% | ▲ +0.01% | $26.12 (+6.27%) |
May 27, 2026 21w ago | 6-K | $25.57 $23.94 | ▼ −6.37% | ▼ −7.58% | $26.12 (+2.15%) |
May 26, 2026 21w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 26, 2026 21w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 22, 2026 22w ago | 6-K | $26.00 $24.25 | ▼ −6.73% | ▼ −8.39% | $26.12 (+0.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers